ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Status:
Not yet recruiting
Trial end date:
2025-02-17
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab
IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at
90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.